Research programme: Alzheimer's disease vaccine intranasal - ID Pharma

Drug Profile

Research programme: Alzheimer's disease vaccine intranasal - ID Pharma

Alternative Names: Alzheimer's disease vaccine intranasal research programme - ID Pharma

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DNAVEC Corporation; National Institute for Longevity Sciences
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Japan (Intranasal)
  • 25 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's Disease pharmacodynamics section
  • 20 Jun 2005 Preclinical trials in Alzheimer's disease in Japan (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top